Skip to content

IBM stellt neuen generativen KI-gestützten Cybersecurity-Assistenten vor

IBM (NYSE: IBM ) gab die Einführung generativer KI-Funktionen in seinen  verwalteten Threat Detection and Response Services bekannt  , die von IBM Consulting-Analysten genutzt werden, um die Sicherheitsabläufe für Kunden zu verbessern und zu optimieren. Der neue IBM Consulting Cybersecurity Assistant basiert auf der Watsonx-Daten- und KI-Plattform von IBM und soll die Identifizierung, Untersuchung und Reaktion auf kritische Sicherheitsbedrohungen beschleunigen und verbessern. Der Cybersecurity Assistant ist nicht nur in die Bedrohungserkennungs- und Reaktionspraxis von IBM Consulting integriert, sondern wird auch Teil von IBM Consulting Advantage sein, der KI-Serviceplattform mit speziell entwickelten KI-Ressourcen, die IBM-Berater in die Lage versetzen sollen, für Kunden einen Mehrwert mit Konsistenz, Wiederholbarkeit, Qualität und Geschwindigkeit zu schaffen. Die Threat Detection and Response (TDR) Services von IBM  können bis zu 85 % der Alarme automatisch eskalieren oder schließen. 1 Und jetzt können die globalen Sicherheitsanalysten von IBM… 

more »IBM stellt neuen generativen KI-gestützten Cybersecurity-Assistenten vor

Labordiagnostik: C2N Diagnostics und Unilabs kooperieren

Unilabs („Unilabs“), ein führender internationaler Anbieter von Diagnosedienstleistungen, und C2N Diagnostics, LLC („C2N“), ein Pionier für fortschrittliche Diagnoselösungen im Bereich der Alzheimer-Krankheit (AD) und verwandter neurologischer Erkrankungen, gaben heute einen wichtigen Meilenstein in der Hirngesundheitsdiagnostik und Forschung in Europa und darüber hinaus bekannt. Unilabs und C2N haben einen mehrjährigen Partnerschaftsvertrag unterzeichnet, der den Zugang zu C2Ns Precivity Portfolio von Bluttests auf exklusiver Basis in Europa, einschliesslich Norwegen, der Schweiz und Grossbritannien, erweitern wird. Die Vereinbarung wird auch den Zugang in Peru, Saudi-Arabien und den Vereinigten Arabischen Emiraten exklusiv über die bestehenden C2N-Partnerschaften hinaus ermöglichen. C2N’s Precivity Portfolio von Bluttests hilft Gesundheitsdienstleistern und Forschern bei der Erkennung von Amyloid-Plaques und neurofibrillären „Tau“-Tangles im Gehirn, die pathologische Kennzeichen der Alzheimer-Krankheit sind. Diese Tests tragen auch dazu bei, Entscheidungen über das medizinische Management und die Behandlung auf der Grundlage der zugrunde liegenden Ursachen… 

more »Labordiagnostik: C2N Diagnostics und Unilabs kooperieren

FDA Approves Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose

Today, the U.S. Food and Drug Administration approved Zurnai, the first nalmefene hydrochloride auto-injector for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. The agency approved the first nasal spray formulation of nalmefene in May 2023. Drug overdose persists as a major public health issue in the U.S., with more than 107,000 reported fatal overdoses occurring in 2023, primarily driven by synthetic opioids like illicit fentanyl. Nalmefene and naloxone are two available options to reverse opioid overdose. The FDA has worked to increase availability and accessibility of both options to encourage harm reduction and reduce overdose death. Nalmefene is an opioid receptor antagonist which is used to treat acute opioid overdose. If nalmefene is administered quickly, it can reverse the effects of opioid overdose, including respiratory depression, sedation… 

more »FDA Approves Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to seven new employees. On August 1, 2024, the Company issued to these employees options to purchase an aggregate of 100,457 shares of the Company’s common stock with an exercise price of $15.47, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. Each of the options vest as to 25% on August 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on August 1, 2028. Each of the… 

more »Cartesian Therapeutics Announces New Employment Inducement Grants

CENTOGENE kicked out by Nasdaq

  • News

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE’S common stock from Nasdaq. The notice indicates that CENTOGENE (the “Company”) remains noncompliant with Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum USD 15 million market value of publicly held shares. CENTOGENE Receives Delisting Notice From Nasdaq

Nipocalimab for the treatment of alloimmunized pregnant women

Johnson & Johnson (NYSE: JNJ) today announced the results from the Phase 2 open-label UNITY study of nipocalimab for the treatment of alloimmunized pregnant woman at risk of early onset severe (EOS) HDFN have been published in The New England Journal of Medicine (NEJM). The UNITY study met its primary endpoint with 54 percent of individuals receiving nipocalimab achieving a live birth at or after 32 weeks gestational age (GA) without the need for IUT. Nipocalimab is currently the only therapy reported to be in clinical development for HDFN, a serious and rare condition that occurs when the blood types of a pregnant individual and the developing fetus are incompatible, potentially causing life-threatening anemia in the fetus or infant.2 These results showed that nipocalimab delayed or prevented severe fetal anemia requiring treatment prenatally and reduced the need for IUTs in… 

more »Nipocalimab for the treatment of alloimmunized pregnant women

Breakthrough: World’s First EB Virus-Related mRNA Therapeutic Cancer Vaccine

WestGene to Advance Clinical Trials Following Dual IND Approvals for World’s First EB Virus-Related mRNA Therapeutic Cancer Vaccine. On 6 August, the Center for Drug Evaluation (CDE) of the NMPA approved the clinical trial application for WGc-043 injection, allowing the initiation of Phase I clinical trials. This dual approval further validates WestGene’s expertise in core mRNA technologies such as delivery vectors and sequence design, and accelerates the commercialisation of effective and low-toxicity anti-tumour mRNA vaccines worldwide. EBV, classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC), infects more than 90% of the world’s population and is associated with more than ten malignancies, including nasopharyngeal carcinoma, lymphoma, gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer and cervical cancer. WGc-043 is now approved in both countries for treating EBV-positive solid tumors and hematologic malignancies.… 

more »Breakthrough: World’s First EB Virus-Related mRNA Therapeutic Cancer Vaccine

Novartis erhält beschleunigte FDA-Zulassung für Fabhalta®

Novartis erhält beschleunigte FDA-Zulassung für Fabhalta® (iptacopan), den ersten und einzigen Komplementinhibitor zur Verringerung der Proteinurie bei primärer IgA-Nephropathie (IgAN). Fabhalta erzielte in der Phase-III-Zwischenanalyse von APPLAUSE-IgAN eine 44%ige Reduktion der Proteinurie gegenüber dem Ausgangswert, verglichen mit 9% im Placebo-Arm, was eine klinisch bedeutsame Reduktion von 38% gegenüber Placebo darstellt (p<0,0001)1Fabhalta ist ein Inhibitor des alternativen Komplementwegs, dessen Aktivierung vermutlich zur Pathogenese von IgAN beiträgt1-4Trotz der derzeitigen Standardbehandlung kommt es bei bis zu 50 % der IgAN-Patienten mit anhaltender Proteinurie innerhalb von 10 bis 20 Jahren nach der Diagnose zu Nierenversagen5-11Dies ist die erste Zulassung aus der Nieren-Pipeline von Novartis, die auch Atrasentan und Zigakibart umfasst

Biomarkers for Glioblastoma

The early detection of glioblastomas, one of the most aggressive forms of brain tumors, is crucial for improving prognosis and treatment outcomes. In recent years, biomarkers have emerged as promising tools for the early detection and diagnosis of these tumors. Biomarkers are biological molecules that can be detected in blood, other bodily fluids, or tissues and indicate normal or pathological processes. Important biomarkers for glioblastomas 1. IDH mutations: Isocitrate dehydrogenase (IDH) mutations are common in low-grade gliomas and secondary glioblastomas, but relatively rare in primary glioblastomas. The presence of IDH mutations can indicate a better prognosis and is often used for glioma classification. 2. 1p/19q co-deletion: This genetic anomaly is characteristic of oligodendroglial tumors and can also be helpful in the diagnosis and prognosis of gliomas. Tumors with this co-deletion often respond better to chemotherapy. 3. MGMT promoter methylation: The methylation of the MGMT promoter…

more »Biomarkers for Glioblastoma

Early detection: Biomarkers for bladder cancer

Currently, several new biomarkers for the early detection of bladder cancer are being researched: 1. Survivin and UBC® Rapid: This biomarker combination shows promising results in detecting bladder cancer, especially aggressive high-grade tumors, in urine samples[2]. 2. Nuclear Matrix Protein 22 (NMP22): This biomarker is released from decaying cells and can be detected in elevated concentrations in the urine of bladder cancer patients[5]. 3. RNA-based multiplex test (Cxbladder®) and epigenetic profiling test (AssureMDx TM): These tests use genetic and epigenetic changes to detect bladder cancer[5]. Sources:[1] Urine test detects bladder cancer up to 12 years in advance https://healthcare-in-europe.com/de/news/urintest-blasenkrebs-12-jahre-voraus.html[2] [PDF] Biomarkers for the detection of bladder cancer | DGUV https://www.dguv.de/medien/ipa/publikationen/ipa-journale/ipa-journale2018/documents/ipa_journal_1803_blasenkrebs_biomarker.pdf[3] [PDF] Verification of biomarkers for early detection of… – DGUV https://www.dguv.de/medien/ipa/publikationen/ipa-journale/ipa-journale2017/documents/ipa_journal_1703_harnblase_biomarker.pdf[4] Test enables early diagnosis of bladder tumor – Prevention online https://www.vorsorge-online.de/vorsorgefinder/ipf-faltblaetter/blasentumor-test-ermoeglicht-fruehzeitige-diagnose/[5] Biomarkers for bladder cancer in urine – PI DE – EAU Patient Information https://patients.uroweb.org/de/biomarker-fur-blasenkrebs-im-urin/